


## Enarodustat

<b>Cat. No.:</b>	HY-109057		
<b>CAS No.:</b>	1262132-81-9		
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>16</sub> N <sub>4</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	340.33		
<b>Target:</b>	HIF/HIF Prolyl-Hydroxylase		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 83.33 mg/mL (244.85 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM		2.9383 mL	14.6916 mL	29.3832 mL
		5 mM		0.5877 mL	2.9383 mL	5.8766 mL
10 mM			0.2938 mL	1.4692 mL	2.9383 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.08 mg/mL (6.11 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (6.11 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.08 mg/mL (6.11 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Enarodustat is a potent and orally active factor prolyl hydroxylase inhibitor, with an EC <sub>50</sub> of 0.22 μM. Enarodustat has the potential for renal anemia treatment.
<b>IC<sub>50</sub> &amp; Target</b>	EC <sub>50</sub> : 0.22 μM (factor prolyl hydroxylase) <sup>[1]</sup>
<b>In Vitro</b>	Enarodustat (JTZ-951) is a potent and orally active factor prolyl hydroxylase inhibitor, with an EC <sub>50</sub> of 0.22 μM. Enarodustat exhibits neither CYP (IC <sub>50</sub> > 100 μM; CYP3A4/5, CYP2C9, CYP2D6, CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2B6) nor hERG (IC <sub>50</sub>

---

	> 100 $\mu$ M) inhibition <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Enarodustat (1 and 3 mg/kg, p.o.) increases hemoglobin levels in a dose-dependent manner with daily oral dosing in rats <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

---

[1]. Ogoshi Y, et al. Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia. ACS Med Chem Lett. 2017 Nov 20;8(12):1320-1325.

---

Caution: Product has not been fully validated for medical applications. For research use only.

### India Contact:

#### Life Technologies (India) Pvt. Ltd.

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444  
Email: [customerservice@lifetechindia.com](mailto:customerservice@lifetechindia.com) Website: [www.lifetechindia.com](http://www.lifetechindia.com)